Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy
The Oncologist · 2024
DOI: 10.1093/oncolo/oyad166 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2024. Verfasst von Justine Panian und 27 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego, Department of Medicine, Division of Hematology-Oncology La Jolla, CA, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nephrectomy, Kidney Neoplasms, Immunotherapy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Even though cytoreductive nephrectomy (CN) was once the standard of care for patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well analyzed or defined in the era of immunotherapy (IO). Materials and Methods This study analyzed pathological outcomes in patients with advanced or metastatic RCC who received IO prior to CN. This was a multi-institutional, retrospective study of patients with advanced or metastatic RCC. Patients were required to receive IO monotherapy or combination therapy prior to radical or partial CN. The primary endpoint assessed surgical pathologic outcomes, including American Joint Committee on Cancer (AJCC) staging and frequency of downstaging, at the time of surgery. Pathologic outcomes were correlated to clinical variables using a Wald-chi squared test from Cox regression in a multi-variable analysis. Secondary outcomes included objective response rate (ORR) defined by response evaluation criteria in solid tumors (RECIST) version 1.1 and progression-free survival (PFS), which were estimated using the Kaplan-Meier method with reported 95% CIs.
Results
Fifty-two patients from 9 sites were included. Most patients were male (65%), 81% had clear cell histology, 11% had sarcomatoid differentiation. Overall, 44% of patients experienced pathologic downstaging, and 13% had a complete pathologic response. The ORR immediately prior to nephrectomy was stable disease in 29% of patients, partial response in 63%, progressive disease in 4%, and 4% unknown. Median follow-up for the entire cohort was 25.3 months and median PFS was 3.5 years (95% CI, 2.1-4.9).
Conclusions
IO-based interventions prior to CN in patients with advanced or metastatic RCC demonstrates efficacy, with a small fraction of patients showing a complete response. Additional prospective studies are warranted to investigate the role of CN in the modern IO-era.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of California San Diego, Department of Medicine, Division of Hematology-Oncology La Jolla, CA, USA.
- University of California San Diego, Department of Urology, La Jolla, CA, USA.
- University of California San Diego, Department of Medicine, Division of Hematology-Oncology, La Jolla, CA, USA.
- Brigham and Women's Hospital, Department of Pathology, Boston, MA, USA.
- Tulane University, Deming Department of Medicine, New Orleans, LA, USA.
- Loyola University Chicago, Department of Cancer Biology and Internal Medicine, Maywood, IL, USA.
ORCID-Profile: Justine Panian, Ava Saidian, Kevin Hakimi, Pedro Barata
Zitieren
APA
Panian, J., Saidian, A., Hakimi, K., Ajmera, A., Anderson, W. J., Barata, P., Berg, S., Signoretti, S., Lee Chang, S., D'Andrea, V., George, D., Dzimitrowicz, H., El Zarif, T., Emamekhoo, H., Gross, E., Kilari, D., Lam, E., Lashgari, I., Psutka, S., …, & McKay, R. R. (2024). Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. The Oncologist. https://doi.org/10.1093/oncolo/oyad166
Vancouver
Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, et al. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. The Oncologist. 2024. doi:10.1093/oncolo/oyad166
BibTeX
@article{Panian2024,
author = {Panian, Justine and Saidian, Ava and Hakimi, Kevin and Ajmera, Archana and Anderson, William J and Barata, Pedro and Berg, Stephanie and Signoretti, Sabina and Lee Chang, Steven and D'Andrea, Vincent and George, Daniel and Dzimitrowicz, Hannah and El Zarif, Talal and Emamekhoo, Hamid and Gross, Evan and Kilari, Deepak and Lam, Elaine and Lashgari, Isabel and Psutka, Sarah and Rauterkus, Grant P and Shabaik, Ahmed and Thapa, Bicky and Wang, Luke and Weise, Nicole and Yim, Kendrick and Zhang, Tian and Derweesh, Ithaar and McKay, Rana R},
title = {Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyad166}
}
EUVIMED